BioMarin Pharmaceuticals, Inc. (BMRN) Posts Q4 GAAP Loss of 43c/Share; Guides FY13
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $66.53 --0%
Revenue Growth %: +32.7%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +32.7%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q4 EPS of ($0.43), $0.16 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $130.96 million versus the consensus estimate of $129.7 million.
Sees FY2013 revenue of $530-$555 million, versus the consensus of $562.80 million. Sees Non-GAAP Adjusted EBITDA (loss) of $(75) to $(50) million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Sees FY2013 revenue of $530-$555 million, versus the consensus of $562.80 million. Sees Non-GAAP Adjusted EBITDA (loss) of $(75) to $(50) million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
- Prabhudas Lilladher Upgrades GE Vernova T&D India (GVTD:IN) to Buy (1)
- Morgan Stanley Downgrades Infineon Technologies (IFX:GY) (IFNNY) to Equalweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
